Share

New Topline Teprotumumab-trbw Data Underscore Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People with Thyroid Eye Disease

Two clinical trials have shown positive topline data that add to the growing body of evidence supporting the efficacy and safety of teprotumumab-trbw for the treatment of Thyroid Eye Disease (TED). Horizon Therapeutics is marketing the drug as TEPEZZA, the first medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of...
Share

Patients with COVID-19 May Develop Thyroid Infection

Study reports the first known case of subacute thyroiditis after COVID-19 infection COVID-19 infection may cause subacute thyroiditis, according to a new case study published in The Journal of Clinical Endocrinology & Metabolism. Subacute thyroiditis is an inflammatory thyroid disease characterized by neck pain and is usually preceded by an upper respiratory tract infection. It may be caused by a viral infection or a post-viral inflammatory reaction, and many...
Share

FDA Approves First Treatment for Thyroid Eye Disease

In January, Endocrine News reported on the possible upcoming availability of teprotumumab as a promising treatment for of thyroid eye disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation, and facial disfigurement. Up to 50% of patients with Graves’ disease...
Share

Older Adults with Hypothyroidism Face Elevated Risk of Death

Increased risk does not impact older adults with subclinical hypothyroidism While older adults with hypothyroidism face an elevated risk of death, individuals with subclinical hypothyroidism, a milder form of underactive thyroid, did not face the same risk, according to new research published in The Journal of Clinical Endocrinology & Metabolism. “Our meta-analysis is the first to...
Share

Slightly Elevated TSH Levels Not a Cause for Referral to Pediatric Endocrinologists

Children with thyroid stimulating hormone (TSH) levels slightly above reference range shouldn’t be referred to pediatric endocrinologists unless there is another cause for clinical concern, according to a paper recently published in the Journal of the Endocrine Society. Researchers led by Perrin C. White, MD, of the Division of Pediatric Endocrinology at the University of...
Share

New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting

New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31. The U.S. Food and Drug Administration is currently evaluating...

Endocrine News provides the latest news and research articles on thyroid conditions and treatment. For more info read this month’s issue of Endocrine News.